BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione  1     Irina Blumenstein  2     Peter Irving  3     Ramona Vladea  4     Dapo Ilo  4     Wen Zhou  4     Gweneth Levy  4     Xuan Yao  4     Iris Dotan  5    
1 University of Calgary, Calgary, Canada
2 JW Goethe University Hospital, Frankfurt, Germany
3 Guy's and St Thomas' Hospital, London, United Kingdom
4 AbbVie Inc., North Chicago, United States
5 Tel Aviv University, Tel Aviv, Israel

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing